Publication Cover
AIDS Care
Psychological and Socio-medical Aspects of AIDS/HIV
Volume 23, 2011 - Issue 9
1,230
Views
28
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES

A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States

, , , &
Pages 1154-1162 | Received 29 Jul 2010, Accepted 25 Nov 2010, Published online: 14 Apr 2011

Figures & data

Figure 1.  Selection of patients with an HIV diagnosis who initiated ARV therapy involving a minimum of two NRTIs plus one NNRTI or one PI (± ritonavir); ARV, antiretroviral; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Figure 1.  Selection of patients with an HIV diagnosis who initiated ARV therapy involving a minimum of two NRTIs plus one NNRTI or one PI (± ritonavir); ARV, antiretroviral; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Figure 2.  Study schematic. 1The index date occurred between July 2003 and December 2007; 2The ARV regimen involved a minimum of two NRTIs plus one NNRTI or one PI (± ritonavir); 3Nonpersistence was defined as discontinuation of the ARV regimen following an allowed 90-day gap between refills or any change to the initial ARV regimen prescribed; ARV, antiretroviral; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Figure 2.  Study schematic. 1The index date occurred between July 2003 and December 2007; 2The ARV regimen involved a minimum of two NRTIs plus one NNRTI or one PI (± ritonavir); 3Nonpersistence was defined as discontinuation of the ARV regimen following an allowed 90-day gap between refills or any change to the initial ARV regimen prescribed; ARV, antiretroviral; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Table 1. Description of regimens.

Table 2. Characteristics of patients (n=2460) included in the study cohort by type of index antiretroviral regimen (NNRTI vs PI).

Figure 3.  Persistence (i.e., time to discontinuation) by type of index ARV regimen (NNRTI-based or PI-based). The difference in time to discontinuation between PI- and NNRTI-based regimens was p < 0.0001 (log-rank test); ARV, antiretroviral; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Figure 3.  Persistence (i.e., time to discontinuation) by type of index ARV regimen (NNRTI-based or PI-based). The difference in time to discontinuation between PI- and NNRTI-based regimens was p < 0.0001 (log-rank test); ARV, antiretroviral; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Table 3. Multivariate risk of regimen discontinuation (n = 2460).

Table 4. Multivariate risk of discontinuation of specific regimens vs EFV/FTC/TDF fixed-dose regimen (n=1261, including n=316 on EFV/FTC/TDF fixed-dose regimen).